AITRICS said Thursday it has won approval from the Ministry of Food and Drug Safety for its AITRICS-VC, or Vital Care, AI software that helps diagnose by predicting the aggravation of patients’ conditions.Vital Care is an AI monitoring system that predicts the deaths of patients at intensive care un
Neurophet said Thursday that the company signed a contract to provide brain disease image analysis service for the Korea National Institute of Health (NIH) to establish research data for reading and studying brain disease image data.“The project to build research data through reading brain disease i
"It is quite possible to globalize Korean medicines and medical supplies.”CEO Huh Kyung-hwa of the Korea Innovative Medicines Consortium (KIMCo) affirmed so during a meeting with reporters to commemorate the second anniversary of the consortium’s establishment.KIMCo is a non-profit foundation set up
GE Healthcare Korea said UGAP (Ultrasound-Guided Attenuation Parameter), which can quantitatively scan for hepatic steatosis of non-alcoholic fatty liver disease (NAFLD) using B-mode ultrasound attenuation coefficient, was recognized by the government as newmedical technology.UGAP makes quantitative
Daehwa Pharmaceutical said Wednesday that it had been notified of the acceptance of the application for new drug approval for Liporaxel/RMX3001, oral paclitaxel (DHP107/RMX3001) drug, from China’s National Medical Products Administration.The indication of Liporaxel/RMX3001 seeking the Chinese permit
The domestic biopharmaceutical businesses’ interests in digital treatment technology were “hot” if a recent industrial fair was any guide.More than 100 industry officials from biopharmaceutical companies, medical institutions, and the digital healthcare sector participated in the “Digital Healthcare
Middle-aged people who sleep less than six hours during weekdays can reduce their risks of depression by catching up on sleep at weekends, a recent study showed.A research team, led by Professor Oh Yoon-hwan of family medicine at Chung Ang University Gwangmyong Hospital, released the paper “Associat
Hanmi Pharmaceutical said it was ready to lead the local dyslipidemia treatment market with Rosuzet (rosuvastatin 10mg+ezetimibe 10mg) because of the treatment’s “distinguished evidence for therapeutic benefits.”At a news conference in Seoul Monday, Hanmi disclosed the results of the RACING trial, s
Genencell said Tuesday it obtained approval from Drugs Controller General of India (DCGI) to conduct phase 2/3 trial of ES16001 (pipeline name: GNC102), an oral Covid-19 treatment candidate.The biotech firm is conducting Covid-19 drug trials in multiple countries.In October, it received the nod to c
Physicians are increasingly emphasizing the importance of managing heart failure (HF), the final complication of cardiovascular disease, and Bayer’s new treatment Verquvo (vericiguat), is drawing attention from the medical community.According to the Korea Heart Failure Fact Sheet released by the Kor
The government is wielding excessive power to lower drug prices without recognizing the values of innovative medicines, an expert said.Kim Sung-ju, an expert advisor for Lee & Ko’s Healthcare Practice Group, published an article in the Korea Pharmaceutical and Bio-Pharma Manufacturers Association’s
The Ministry of Health and Welfare’s health insurance policy committee set the reimbursement price of Fexuclue (fexuprazan), a treatment for gastroesophageal reflux disease (GERD) developed by Daewoong Pharmaceutical, at 939 won ($0.73) per tablet. Fexuclue is the nation’s 34th novel drug.At a meeti
Amgen Korea and Jeil Pharmaceutical said they signed an agreement to jointly sell Repatha (evolucumab), lipid-lowering drugs for atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia starting in June.Under the agreement, Amgen Korea and Jeil Pharmaceutical will conduct Repatha sale
Korean pharmaceutical and biotech companies are using various open innovation tools to raise competitiveness in new drug development in the global market.In the past, Korean drugmakers conducted research in secrecy due to the risk of technology leakage. But now, they actively get technologies and bu
Hugel said Friday it obtained marketing approval for Letybo 50Unit, a botulinum toxin (BTX), from Poland’s Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL) on May 25.Earlier in 2019, Hugel and Austrian pharmaceutical firm Croma began phase 3 trials of the B
It is difficult to treat rare and intractable diseases because causes and treatment methods remain unclear. However, new therapeutics are emerging one after another to fight these diseases.So far, treatments for rare and intractable diseases have aimed to slow the disease progression or relieve symp
The government selected Humedix’s “polynucleotide sodium” (PN) technology as a national research project that will enhance Korea’s technological power, Humedix said.The Ministry of Trade, Industry and Energy picked Humedix’s “medical PN-based production technology with an average molecular weight of
Daewoong Pharmaceutical’s sales of prescription drugs have expanded significantly this year.In April, Daewoong’s revenue from prescription drugs exceeded 70 billion won ($55.69 million).Accumulated sales in the first four months of 2022 recorded 267.5 billion won, up 14.3 percent from the same perio
Boryung Corp. said it recorded the largest quarterly earnings in the first quarter of 2022 in its history, continuing a solid growth after 2021.The company’s sales and operating profit posted 170.6 billion won ($134.4 million), and 18.7 billion won in the first quarter, up 26 percent and 36 percent
A government official said Korea’s first homegrown digital therapeutic would get marketing approval within this year.Kang Young-kyu, director of the Digital Health Devices Division at the Ministry of Food and Drug Safety (MFDS), said 10 digital therapeutics (DTx) were in clinical trials. At least on